Journal of Surgical Research
Volume 140, Issue 2 , Pages 199-203, 15 June 2007

Mast Cell-Derived Cathepsin g: A Possible Role in The Adverse Remodeling of The Failing Human Heart

  • Jama Jahanyar, M.D., Ph.D.

      Affiliations

    • Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, Texas
    • Corresponding Author InformationTo whom correspondence and reprint requests should be addressed at Michael E. DeBakey Department of Surgery, Division of Transplant and Assist Devices, Baylor College of Medicine, One Baylor Plaza, Houston, Texas 77030.
  • ,
  • Keith A. Youker, Ph.D.

      Affiliations

    • Methodist DeBakey Heart Center, The Methodist Hospital, Houston, Texas
  • ,
  • Matthias Loebe, M.D., Ph.D.

      Affiliations

    • Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, Texas
  • ,
  • Christian Assad-Kottner, M.D.

      Affiliations

    • Methodist DeBakey Heart Center, The Methodist Hospital, Houston, Texas
  • ,
  • Michael M. Koerner, M.D., Ph.D.

      Affiliations

    • Department of Medicine, Baylor College of Medicine, Houston, Texas
  • ,
  • Guillermo Torre-Amione, M.D., Ph.D.

      Affiliations

    • Methodist DeBakey Heart Center, The Methodist Hospital, Houston, Texas
  • ,
  • George P. Noon, M.D.

      Affiliations

    • Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, Texas

Received 4 December 2006 published online 11 April 2007.

Background

The role of cardiac mast cells (MCs) in the progression to heart failure has recently become increasingly evident. Cathepsin g is a neutrophil- and mast cell-derived protease, which can convert angiotensin I to angiotensin II and thereby activate the TGF-β pathway, resulting in myocyte necrosis, hypertrophy, and increased fibrosis. This study focuses on mast cell-derived cathepsin g in the human heart during heart failure and following mechanical unloading by means of heart-assist devices (LVADs).

Materials and methods

Myocardial tissue was obtained from 10 patients with end-stage cardiomyopathy at the time of LVAD implantation (pre-LVAD) and following orthotopic heart transplantation (post-LAVD). In addition, biopsies of four normal hearts served as a control group. Paraffin-embedded sections were dual stained for cathepsin g and tryptase, a known marker for mast cells, using standard immunohistochemistry protocols. Total cathepsin g positive mast cells were counted.

Results

No cathepsin g positive MCs were found in normal hearts. However, we found evidence for cathepsin g in cardiac MCs in heart failure tissues (pre-LVAD). During heart failure, 46% of total MCs were cathepsin g positive as compared to after mechanical unloading, where only 11% of total MCs were cathepsin g positive (P < 0.001).

Conclusion

Heart failure causes an increase of myocardial MCs. We have provided evidence that cathepsin g positive MCs accumulate during heart failure and their total percentage decreases after ventricular unloading. This coincides with the decrease in myocyte necrosis, hypertrophy, and fibrosis. Thus, cathepsin g may play a role in the progression to heart failure by activating angiotensin II, leading to detrimental effects on the heart.

Key Words: cathepsin g, heart failure, mast cells, LVAD, chymase, remodeling

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0022-4804(07)00120-5

doi:10.1016/j.jss.2007.02.040

Journal of Surgical Research
Volume 140, Issue 2 , Pages 199-203, 15 June 2007